Login Register Cart 0
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Efficacy and Safety of Lobaplatin-TACE in the Treatment of Primary Hepatocellular Carcinoma: A Retrospective Study

Author(s): Haohao Lu, Chuansheng Zheng*, Bin Liang and Bin Xiong

Volume 23, Issue 4, 2023

Published on: 20 August, 2022

Page: [461 - 469] Pages: 9

DOI: 10.2174/1871520622666220601115458

open access plus

Abstract

Purpose: To investigate the safety and efficacy of lobaplatin-TACE in treating primary hepatocellular carcinoma.

Methods: The data of 536 patients who underwent TACE in the interventional department from January 2016 to January 2020 were collected. Patients were divided into two groups according to the chemotherapeutic drugs used in TACE.: the epirubicin-TACE group (N = 260) and the lobaplatin-TACE group (N = 276). Primary study endpoint: (1) The tumor response after TACE; (2) The survival rates; Secondary study endpoints:(1) Changes in liver function and blood routine before and after TACE; (2) Occurrence of the post-embolization syndrome and infection after TACE.

Results: The ORR was 35.0% in the epirubicin-TACE group and 51.1% in the lobaplatin-TACE group (p=0.001). The DCR was 73.1% in the epirubicin-TACE group and 82.2% in the lobaplatin-TACE group (p=0.011). The 6-month, 9- month, 12-month, and 15-month survival rates were higher in the lobaplatin-TACE group than in the epirubicin-TACE group (p=0.029, p=0.001, p=0.005, p=0.002). mOS: Epirubicin-TACE group,14.8 months; Lobaplatin-TACE group,18.6 months (p=0.007). mPFS: Epirubicin-TACE group,9.5 months; Lobaplatin-TACE group,12.8 months (P =0.000). There was no statistical difference in ALT, AST, total bilirubin and Leucocyte after TACE between the two groups (p=0.343, p=0.368, p=0.288, p=0.359). The platelet decrease after TACE was more significant in the lobaplatin- TACE group than in the epirubicin-TACE group (p=0.046). There was no statistical difference in the incidence rate of abdominal pain, fever and infection after TACE between the two groups (p=0.502, p=0.602, p=0.726). The incidence of vomiting after TACE in the lobaplatin-TACE group was higher than that in the epirubicin-TACE group (p=0.003).

Conclusion: Lobaplatin-TACE has a higher tumor response rate and survival rate. Lobaplatin-TACE is a safe and effective treatment strategy; it is worthy of clinical application.

Keywords: Lobaplatin, lipiodol emulsion, TACE, Transarterial chemoembolization, hepatocellular carcinoma, tumor response, survival rate

« Previous Next »
Graphical Abstract

[1]
Clark, T.; Maximin, S.; Meier, J.; Pokharel, S.; Bhargava, P. Hepatocellular carcinoma: Review of epidemiology, screening, imaging diag-nosis, response assessment, and treatment. Curr. Probl. Diagn. Radiol., 2015, 44(6), 479-486.
[http://dx.doi.org/10.1067/j.cpradiol.2015.04.004] [PMID: 25979220]
[2]
Budny, A.; Kozłowski, P.; Kamińska, M.; Jankiewicz, M.; Kolak, A.; Budny, W.; Niemunis-Sawicka, J.; Szczypior, G.; Kurniawka, B.; Burdan, F. Epidemiology and risk factors of hepatocellular carcinoma. Pol Merkur Lekarski, 2017, 43(255), 133-139.
[3]
Hartke, J.; Johnson, M.; Ghabril, M. The diagnosis and treatment of hepatocellular carcinoma. Semin. Diagn. Pathol., 2017, 34(2), 153-159.
[http://dx.doi.org/10.1053/j.semdp.2016.12.011] [PMID: 28108047]
[4]
Friedman, M.A.; Volberding, P.A.; Cassidy, M.J.; Resser, K.J.; Wasserman, T.H.; Phillips, T.L. Therapy for hepatocellular cancer with intrahepatic arterial adriamycin and 5-fluorouracil combined with whole-liver irradiation: A northern California oncology group study. Cancer Treat. Rep., 1979, 63(11-12), 1885-1888.
[PMID: 230895]
[5]
Reuter, S.R. The current status of angiography in the evaluation of cancer patients. Cancer, 1976, 37(1)(Suppl.), 532-541.
[http://dx.doi.org/10.1002/1097-0142(197601)37:1+<532::AIDCNCR2820370718>3.0.CO;2-K] [PMID: 942883]
[6]
Casadaban, L.C.; Minocha, J.; Bui, J.T.; Knuttinen, M.G.; Ray, C.E., Jr; Gaba, R.C. Conventional ethiodized oil transarterial chemoemboli-zation for treatment of hepatocellular carcinoma: Contemporary single-center review of clinical outcomes. AJR Am. J. Roentgenol., 2016, 206(3), 645-654.
[http://dx.doi.org/10.2214/AJR.15.14758] [PMID: 26901023]
[7]
Lencioni, R.; de Baere, T.; Soulen, M.C.; Rilling, W.S.; Geschwind, J.F. Lipiodol transarterial chemoembolization for hepatocellular carci-noma: A systematic review of efficacy and safety data. Hepatology, 2016, 64(1), 106-116.
[http://dx.doi.org/10.1002/hep.28453] [PMID: 26765068]
[8]
Ni, J.Y.; Fang, Z.T.; An, C.; Sun, H.L.; Huang, Z.M.; Zhang, T.Q.; Jiang, X.Y.; Chen, Y.T.; Xu, L.F.; Huang, J.H. Comparison of albumin-bilirubin grade, platelet-albumin-bilirubin grade and Child-Turcotte-Pugh class for prediction of survival in patients with large hepatocellu-lar carcinoma after transarterial chemoembolization combined with microwave ablation. Int. J. Hyperthermia, 2019, 36(1), 841-853.
[http://dx.doi.org/10.1080/02656736.2019.1646927] [PMID: 31452408]
[9]
Chen, S.; Yu, W.; Zhang, K.; Liu, W.; Chen, Q. Transarterial chemoembolization for unresectable hepatocellular carcinoma: A comparison of the efficacy and safety of 2 embolic agents. Medicine (Baltimore), 2018, 97(21), e10832.
[http://dx.doi.org/10.1097/MD.0000000000010832] [PMID: 29794774]
[10]
Tsoris, A.; Marlar, C.A. Use of the child pugh score in liver disease. In: StatPearls; StatPearls Publishing: Treasure Island, (FL), 2021.
[11]
Llovet, J.M.; Lencioni, R. mRECIST for HCC: Performance and novel refinements. J. Hepatol., 2020, 72(2), 288-306.
[http://dx.doi.org/10.1016/j.jhep.2019.09.026] [PMID: 31954493]
[12]
Lencioni, R.; Montal, R.; Torres, F.; Park, J.W.; Decaens, T.; Raoul, J.L.; Kudo, M.; Chang, C.; Ríos, J.; Boige, V.; Assenat, E.; Kang, Y.K.; Lim, H.Y.; Walters, I.; Llovet, J.M. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J. Hepatol., 2017, 66(6), 1166-1172.
[http://dx.doi.org/10.1016/j.jhep.2017.01.012] [PMID: 28131794]
[13]
Facciorusso, A.; Licinio, R.; Muscatiello, N.; Di Leo, A.; Barone, M. Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients. World J. Hepatol., 2015, 7(16), 2009-2019.
[http://dx.doi.org/10.4254/wjh.v7.i16.2009] [PMID: 26261690]
[14]
Chinese college of interventionalists, chinese medical doctor association. Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma. Chin. J. Hepatol., 2019, 27(3), 172-181.
[http://dx.doi.org/10.3760/cma.j.issn.1007-3418.2019.03.003]
[15]
Tam, K.Y.; Leung, K.C.; Wang, Y.X. Chemoembolization agents for cancer treatment. Eur. J. Pharm. Sci., 2011, 44(1-2), 1-10.
[http://dx.doi.org/10.1016/j.ejps.2011.06.013] [PMID: 21726636]
[16]
Kawamura, Y.; Ikeda, K.; Kumada, H. Strategy for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoemboli-zation using epirubicin. Cancer Chemother, 2010, 37(3), 402-407.
[17]
McKeage, M.J. Lobaplatin: A new antitumour platinum drug. Expert Opin. Investig. Drugs, 2001, 10(1), 119-128.
[http://dx.doi.org/10.1517/13543784.10.1.119] [PMID: 11116285]
[18]
Tian, W.; Hao, S.; Gao, B.; Jiang, Y.; Zhang, X.; Zhang, S.; Guo, L.; Zhao, J.; Zhang, G.; Chen, Y.; Li, Z.; Luo, D. Lobaplatin inhibits breast cancer progression, cell proliferation while it induces cell apoptosis by downregulating MTDH expression. Drug Des. Devel. Ther., 2018, 12, 3563-3571.
[http://dx.doi.org/10.2147/DDDT.S163157] [PMID: 30464390]
[19]
Xu, L.; Wang, B.; Gao, M.; Zhang, Y.; Qi, Q.; Li, T.; Li, C.; Wang, A.; Li, Y. Intrapleural combination therapy with lobaplatin and eryth-romycin for non-small cell lung cancer-mediated malignant pleural effusion. Thorac. Cancer, 2018, 9(8), 950-955.
[http://dx.doi.org/10.1111/1759-7714.12768] [PMID: 29917319]
[20]
Chen, Z.; Xu, G.; Wu, D.; Wu, S.; Gong, L.; Li, Z.; Luo, G.; Hu, J.; Chen, J.; Huang, X.; Chen, C.; Jiang, Z.; Li, X. Lobaplatin induces py-roptosis through regulating cIAP1/2, Ripoptosome and ROS in nasopharyngeal carcinoma. Biochem. Pharmacol., 2020, 177, 114023.
[http://dx.doi.org/10.1016/j.bcp.2020.114023] [PMID: 32413426]
[21]
Pei, W.; Zhou, S.; Zhang, J.; Zhou, H.; Chen, H.; Bi, J.; Zheng, Z.; Liu, Z.; Jiang, Z.; Wang, Z.; Liu, Q.; Wang, X.; Liang, J.; Feng, Q. Lobaplatin-based hyperthermic intraperitoneal chemotherapy for patients with peritoneal metastasis from appendiceal and colorectal can-cer: safety and efficacy profiles. Cancer Manag. Res., 2020, 12, 12099-12110.
[http://dx.doi.org/10.2147/CMAR.S281434] [PMID: 33262658]
[22]
Zhou, H.T.; Jiang, J.; Guan, X.; Su, H.; Liang, J.W.; Pei, W.; Wang, Z.; Liu, Z.; Jiang, Z.; Liu, Q.; Zhou, Z.X.; Jin, W.S.; Wang, X.S. The short-term effect analysis of intraoperative intraperitoneal perfusion chemotherapy with lobaplatin for colorectal cancer. J. BUON, 2019, 24(2), 442-448.
[PMID: 31127989]
[23]
Zhong, Y.; Zhang, J.; Bai, X.; Sun, Y.; Liu, H.; Ma, S.; Li, Y.; Kang, W.; Ma, F.; Li, W.; Tian, Y. Lobaplatin in prophylactic hyperthermic intraperitoneal chemotherapy for advanced gastric cancer: Safety and efficacy profiles. Cancer Manag. Res., 2020, 12, 5141-5146.
[http://dx.doi.org/10.2147/CMAR.S249838] [PMID: 32636676]
[24]
Wu, Q.; Qin, S.K.; Teng, F.M.; Chen, C.J.; Wang, R. Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells. J. Hematol. Oncol., 2010, 3(1), 43.
[http://dx.doi.org/10.1186/1756-8722-3-43] [PMID: 21034513]
[25]
He, M.K.; Zou, R.H.; Wei, W.; Shen, J.X.; Zhao, M.; Zhang, Y.F.; Lin, X.J.; Zhang, Y.J.; Guo, R.P.; Shi, M. Comparison of stable and unstable ethiodized oil emulsions for transarterial chemoembolization of hepatocellular carcinoma: Results of a single-center double-blind prospective randomized controlled trial. J. Vasc. Interv. Radiol., 2018, 29(8), 1068-1077.e2.
[http://dx.doi.org/10.1016/j.jvir.2018.03.027] [PMID: 30042075]
[26]
Zhao, G.S.; Li, C.; Liu, Y.; Ren, Z.Z.; Yuan, X.L.; Zhou, J.; Zhang, Y.W.; Zhang, M. 350-560 μm gelatin sponge particles combined with transcatheter arterial chemoembolization for the treatment of elderly hepatocellular carcinoma: The safety and efficacy. Medicine (Baltimore), 2017, 96(16), e6629.
[http://dx.doi.org/10.1097/MD.0000000000006629] [PMID: 28422858]
[27]
Chen, Y.; Li, W.; Yang, Q.; Chen, L.; Zeng, C. Uninfluenced alpha-fetoprotein and treatment of liver primary carcinoma by lobaplatin in combination with 5-fluorouracil and doxorubicin via chemoembolization and transarterial chemoembolization. Cell. Mol. Biol., 2020, 66(3), 48-51.
[http://dx.doi.org/10.14715/cmb/2020.66.3.7] [PMID: 32538746]
[28]
Peng, S.; Yang, Q.X.; Zhang, T.; Lu, M.J.; Yang, G.; Liu, Z.Y.; Zhang, R.; Zhang, F.J. Lobaplatin-TACE combined with radioactive 125I seed implantation for treatment of primary hepatocellular carcinoma. Asian Pac. J. Cancer Prev., 2014, 15(13), 5155-5160.
[http://dx.doi.org/10.7314/APJCP.2014.15.13.5155] [PMID: 25040967]
[29]
He, M.; Li, Q.; Shen, J.; Tan, G.; Li, Q.; Lai, J.; Wei, W.; Zhang, Y.; Zou, R.; Chen, M.; Guo, R.; Shi, M. Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma. Cancer Med., 2019, 8(9), 4200-4213.
[http://dx.doi.org/10.1002/cam4.2355] [PMID: 31207163]
[30]
Wang, N.; Lv, Y.Z.; Xu, A.H.; Huang, Y.R.; Peng, L.; Li, J.R. Application of lobaplatin in trans-catheter arterial chemoembolization for primary hepatic carcinoma. Asian Pac. J. Cancer Prev., 2014, 15(2), 647-650.
[http://dx.doi.org/10.7314/APJCP.2014.15.2.647] [PMID: 24568472]
[31]
Zhou, B.; Shan, H.; Zhu, K.S.; Jiang, Z.B.; Guan, S.H.; Meng, X.C.; Zeng, X.C. Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation. J. Vasc. Interv. Radiol., 2010, 21(3), 333-338.
[http://dx.doi.org/10.1016/j.jvir.2009.11.006] [PMID: 20116286]
[32]
Lima, M.; Dutra, S.; Gomes, F.V.; Bilhim, T.; Coimbra, É. Risk factors for the development of postembolization syndrome after transarte-rial chemoembolization for hepatocellular carcinoma treatment. Acta Med. Port., 2018, 31(1), 22-29.
[http://dx.doi.org/10.20344/amp.8976] [PMID: 29573765]
[33]
Khalaf, M.H.; Sundaram, V.; AbdelRazek Mohammed, M.A.; Shah, R.; Khosla, A.; Jackson, K.; Desai, M.; Kothary, N. A predictive mod-el for postembolization syndrome after transarterial hepatic chemoembolization of hepatocellular carcinoma. Radiology, 2019, 290(1), 254-261.
[http://dx.doi.org/10.1148/radiol.2018180257] [PMID: 30299233]
[34]
Zhao, C.; Wang, X.J.; Wang, S.; Feng, W.H.; Shi, L.; Yu, C.P. Lobaplatin combined floxuridine/pirarubicin-based transcatheter hepatic arterial chemoembolization for unresectable primary hepatocellular carcinoma. Asian Pac. J. Cancer Prev., 2014, 15(5), 2057-2060.
[http://dx.doi.org/10.7314/APJCP.2014.15.5.2057] [PMID: 24716934]
[35]
Han, S.; Ye, Y.; Wu, J.; Li, B.; Zhang, G.; Jin, K.; Tang, R.; Huang, W.; Chao, M.; Ding, K. Procalcitonin Levels in Post TACE Infection. Cancer Manag. Res., 2020, 12, 12197-12203.
[http://dx.doi.org/10.2147/CMAR.S281667] [PMID: 33273856]
[36]
Arslan, M.; Degirmencioglu, S. Liver abscesses after transcatheter arterial embolization. J. Int. Med. Res., 2019, 47(3), 1124-1130.
[http://dx.doi.org/10.1177/0300060518816875] [PMID: 30614336]
[37]
Zhou, N.N.; Zhao, Y.Y.; Zhai, L.Z.; Ruan, C.M.; Yang, Y.P.; Huang, Y.; Hou, X.; Chen, L.K.; Zhou, T.; Zhang, L. The efficacy and toxici-ty of lobaplatin-contained chemotherapy in extensive-stage small-cell lung cancer. J. Cancer, 2018, 9(13), 2232-2236.
[http://dx.doi.org/10.7150/jca.24557] [PMID: 30026818]
[38]
Wu, Y.; Xu, X.Y.; Yan, F.; Sun, W.L.; Zhang, Y.; Liu, D.L.; Shen, B. Retrospective study of the efficacy and toxicity of lobaplatin in com-bined chemotherapy for metastatic breast cancer. OncoTargets Ther., 2019, 12, 4849-4857.
[http://dx.doi.org/10.2147/OTT.S192373] [PMID: 31417282]
[39]
Lv, Y.; Xu, A.; Wang, N.; Mu, K.; Wang, Z.; Zhao, L.; Huang, Y.; Peng, L.; Xiang, K.; Hu, D.; Qi, J. Retrospective study of TACE in the treatment of lobaplatin-induced thrombocytopenia in primary hepatocellular carcinoma. J. Buon, 2019, 24(6), 2385-2393.
[PMID: 31983110]
[40]
Lv, P.; Yang, S.; Wu, F.; Liu, W.; Qin, H.; Tang, X.; Liu, Z.; Gao, H. Single-nucleotide polymorphisms (rs342275, rs342293, rs7694379, rs11789898, and rs17824620) showed significant association with lobaplatin-induced thrombocytopenia. Gene, 2019, 713, 143964.
[http://dx.doi.org/10.1016/j.gene.2019.143964] [PMID: 31279707]
[41]
Blackburn, H.; West, S. Management of postembolization syndrome following hepatic transarterial chemoembolization for primary or metastatic liver cancer. Cancer Nurs., 2016, 39(5), E1-E18.
[http://dx.doi.org/10.1097/NCC.0000000000000302] [PMID: 26484962]
[42]
Kuwaki, K.; Nouso, K.; Miyashita, M.; Makino, Y.; Hagihara, H.; Moriya, A.; Adachi, T.; Wada, N.; Yasunaka, Y.; Yasunaka, T.; Takeuchi, Y.; Onishi, H.; Nakamura, S.; Ikeda, F.; Shiraha, H.; Takaki, A.; Okada, H. The efficacy and safety of steroids for preventing postembolization syndrome after transcatheter arterial chemoembolization of hepatocellular carcinoma. Acta Med. Okayama, 2019, 73(4), 333-339.
[http://dx.doi.org/10.18926/AMO/56935] [PMID: 31439956]

Rights & Permissions Print Cite
Article Metrics
12
© 2024 Bentham Science Publishers | Privacy Policy